March 23, 2016
1 min read
Save

ASCO names new CEO

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Clifford A. Hudis, MD, FACP, has been named the next CEO of ASCO.

Hudis currently serves as chief of the breast medicine service, vice president for government relations and chief advocacy officer at Memorial Sloan Kettering Cancer Center. He also is professor of medicine at Weill Cornell Medical College.

Hudis served as president of ASCO from 2013 to 2014.

Clifford Hudis

Clifford A. Hudis

“Dr. Hudis is the best leader to advance ASCO’s vision in a time of rapid technological, scientific and societal change,” Julie M. Vose, MD, MBA, FASCO, president of ASCO, said in a press release. “As a recent president and one of ASCO’s most active volunteers for more than 2 decades, he has shown a remarkable commitment to our mission of improving patient care.”

Hudis — who specializes in breast cancer and cancer prevention — also served on ASCO’s Board of Directors and chaired the organization’s Integrated Technology Committee.

“From my first meetings as a senior fellow in 1990, to my earliest opportunities to present data — sharing the stage with luminaries and earlier leaders in my field — to the ways ASCO allowed me to contribute to improvements in cancer care, I have been excited by the service that the society offers its members and patients around the world,” Hudis said. “My passion for ASCO’s mission is the reason I have dedicated so much of my professional life to the organization, and I am thrilled to join the staff and volunteers as we enter an exciting new era in all aspects of cancer prevention and treatment.”

Hudis will assume his new position June 27, 2016. He succeeds Allen S. Lichter, MD, FASCO, who is retiring after 10 years as ASCO CEO.

“All of us on the Board are grateful to Dr. Lichter for putting ASCO and its members at the vanguard of cancer science and patient care,” Vose said. “He leaves ASCO in an incredibly strong position to meet the needs of physicians and patients worldwide.”